ENTX · Entera Bio Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | $0 | $134.0K | $365.0K | $365.0K |
| Cost of Revenue | $42.0K | $172.0K | $0 | $101.0K | $300.0K | $209.0K |
| Gross Profit | $0 | $9.0K | $0 | $33.0K | $65.0K | $156.0K |
| R&D | $6.00M | $4.50M | $4.51M | $5.85M | $6.38M | $6.40M |
| SG&A | $340.0K | $5.09M | $4.43M | $7.25M | $4.85M | $4.89M |
| Total Operating Expenses | $11.53M | $9.59M | $8.89M | $13.05M | $11.23M | - |
| D&A | $30.0K | $46.0K | $56.0K | $64.0K | $63.0K | $225.0K |
| Operating Income | ($11.53M) | ($9.59M) | ($8.89M) | ($13.02M) | ($11.17M) | ($11.13M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $14.0K | $29.0K | $137.0K | $20.0K | $20.0K |
| Net Income | ($11.44M) | ($9.54M) | ($8.89M) | ($13.07M) | ($11.22M) | ($9.98M) |
| EPS - Basic | $0.25 | $0.25 | $0.31 | $0.47 | - | $0.54 |
| EPS - Diluted | $0.25 | $0.25 | $0.31 | $0.47 | - | $0.55 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.11M | $8.66M | $11.02M | $12.31M | $24.89M | $8.59M |
| Accounts Receivable | $0 | $126.0K | $0 | $246.0K | $255.0K | $255.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $448.0K | $132.0K | $83.0K | $17.0K | $164.0K | $1.33M |
| Current Assets | $15.30M | $8.97M | $11.26M | $12.85M | $9.11M | $9.11M |
| Total Assets | $15.99M | $9.39M | $11.77M | $13.13M | $9.72M | $10.26M |
| Current Liabilities | $2.20M | $1.18M | $1.09M | $1.34M | $3.16M | $3.27M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.89M | $1.31M | $1.38M | $1.37M | $3.42M | $3.60M |
| Stockholders' Equity | $13.10M | $8.08M | $10.39M | $11.75M | $22.57M | $6.67M |
| Retained Earnings | ($125.37M) | ($113.93M) | ($104.39M) | ($95.50M) | ($82.43M) | ($72.89M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.37M) | ($6.82M) | ($7.31M) | ($12.50M) | ($10.56M) | ($10.42M) |
| Investing Cash Flow | ($107.0K) | ($3.0K) | ($17.0K) | ($102.0K) | ($53.0K) | ($86.0K) |
| Financing Cash Flow | $13.71M | $4.48M | $6.04M | $13.0K | $4.05M | $3.92M |
| CapEx | $107.0K | $3.0K | $17.0K | $47.0K | $53.0K | - |
| Free Cash Flow | ($7.48M) | ($6.82M) | ($7.33M) | ($12.55M) | ($10.61M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 0.0% | 5.0% | - | 24.6% | 17.8% | 42.7% |
| Operating margin | -27450.0% | -5295.6% | - | -9714.2% | -3059.7% | -3050.1% |
| EBITDA margin | -27378.6% | -5270.2% | - | -9666.4% | -3042.5% | -2988.5% |
| Net margin | -27235.7% | -5271.3% | - | -9754.5% | -3072.9% | -2735.1% |
| Free cash flow margin | -17802.4% | -3768.5% | - | -9362.7% | -2906.8% | - |
| FCF / Net income | 0.65 | 0.71 | 0.82 | 0.96 | 0.95 | - |
| R&D / Revenue | 14295.2% | 2485.6% | - | 4364.2% | 1748.5% | 1752.9% |
| SG&A / Revenue | 809.5% | 2814.9% | - | 5412.7% | 1329.0% | 1340.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -71.5% | -101.6% | -75.6% | -99.6% | -115.4% | -97.3% |
| Return on equity | -87.3% | -118.1% | -85.6% | -111.2% | -49.7% | -149.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.94 | 7.63 | 10.32 | 9.58 | 2.88 | 2.78 |
| Quick ratio | 6.94 | 7.63 | 10.32 | 9.58 | 2.88 | 2.78 |
| Cash ratio | 3.23 | 7.36 | 10.10 | 9.18 | 7.87 | 2.63 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.22 | 1.16 | 1.13 | 1.12 | 0.43 | 1.54 |
| Liabilities / Assets | 0.18 | 0.14 | 0.12 | 0.10 | 0.35 | 0.35 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.02 | 0.00 | 0.01 | 0.04 | 0.04 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 0d | 254d | - | 670d | 255d | 255d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 3893d | 280d | - | 61d | 200d | 2323d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 7.8x | 8.5x | 1.9x | 1.6x | - | 2.0x |
| P / B | 6.8x | 9.9x | 1.7x | 1.6x | - | 3.0x |
| P / S | 2133.6x | 441.0x | - | 142.4x | - | 54.5x |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -76.8% | - | -100.0% | -63.3% | 0.0% | 54.7% |
| Revenue CAGR (3y) | -32.1% | -20.8% | - | -17.2% | -10.0% | - |
| Revenue CAGR (5y) | -35.1% | -5.2% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | -49.2% | -58.3% | 500.0% |
| Operating income growth (YoY) | -20.3% | -7.8% | 31.7% | -16.6% | -0.3% | 2.8% |
| Net income growth (YoY) | -19.9% | -7.3% | 32.0% | -16.5% | -12.4% | 7.5% |
| EPS growth (YoY) | 0.0% | -19.4% | -34.0% | - | - | -38.2% |
| EPS CAGR (3y) | -19.0% | - | -17.4% | -19.2% | - | - |
| EPS CAGR (5y) | -14.6% | -22.4% | -16.9% | - | - | - |
| FCF growth (YoY) | -9.6% | 6.9% | 41.6% | -18.2% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 62.1% | -22.2% | -11.6% | -47.9% | 238.6% | -44.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$502.0K totalService$502.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-6.39
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Entera Bio Ltd. against the 5 most active filers in the same SIC group.